Taken together, although there are issues to be considered in the future, such as the presence or absence of adverse effects associated with long-term drug use, our results provide the first scientific evidence to our knowledge for the role of signaling inhibitors in patients with NS with congenital heart defects carrying heterozygous AD LZTR1 mutations. Here, LZTR1 is linked to congenital heart disease.